Now available LIFYORLI™

LIFYORLI™ (relacorilant) is indicated in combination with nab‑paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens, at least one of which included bevacizumab.

Please see full prescribing information here.